| Literature DB >> 35745722 |
Bruno Vincenzo Fiod Riccio1, André Luiz Carneiro Soares do Nascimento1, Andréia Bagliotti Meneguin1, Camila Fernanda Rodero1, Kaio Pini Santos1, Rafael Miguel Sábio1, Sarah Raquel de Annunzio2, Carla Raquel Fontana2, Hernane da Silva Barud3, Priscileila Colerato Ferrari4, Marlus Chorilli1.
Abstract
Trans-resveratrol can promote various dermatological effects. However, its high crystallinity decreases its solubility and bioavailability. Therefore, solid dispersions have been developed to promote its amorphization; even so, they present as powders, making cutaneous controlled drug delivery unfeasible and an alternative necessary for their incorporation into other systems. Thus, polyvinylpyrrolidone (PVP) films were chosen with the aim of developing a controlled delivery system to treat inflammation and bacterial infections associated with atopic dermatitis. Four formulations were developed: two with solid dispersions (and trans-resveratrol) and two as controls. The films presented with uniformity, as well as bioadhesive and good barrier properties. X-ray diffraction showed that trans-resveratrol did not recrystallize. Fourier-transform infrared spectroscopy (FT-IR) and thermal analysis evidenced good chemical compatibilities. The in vitro release assay showed release values from 82.27 ± 2.60 to 92.81 ± 2.50% (being a prolonged release). In the in vitro retention assay, trans-resveratrol was retained in the skin, over 24 h, from 42.88 to 53.28%. They also had low cytotoxicity over fibroblasts. The in vivo assay showed a reduction in inflammation up to 66%. The films also avoided Staphylococcus aureus's growth, which worsens atopic dermatitis. According to the results, the developed system is suitable for drug delivery and capable of simultaneously treating inflammation and infections related to atopic dermatitis.Entities:
Keywords: amorphization; anti-inflammatory activity; antimicrobial effect; crystallinity; skin permeation; solubility; technological innovation
Year: 2022 PMID: 35745722 PMCID: PMC9230924 DOI: 10.3390/pharmaceutics14061149
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.525
Solid dispersion and PVP films samples.
| Formulation | Chitosan (g) | TPGS (%) | |
|---|---|---|---|
| SD-1:9 | 1:9 | - | 1 |
| SD-1:3 | 1:3 | - | 1 |
| PVP-SD-1:9 | 1:9 | - | 1 |
| PVP-SD-1:3 | 1:3 | - | 1 |
| C-PVP-1:9 | - | 0.90 | 1 |
| C-PVP-1:3 | - | 0.75 | 1 |
Footnote: SD: solid dispersions. Control samples (C-) did not contain the trans-resveratrol.
Grades of Cytotoxicity (ISO 10993-5:2009).
| Grade (Cytotoxicity) | Cytotoxicity Zone |
|---|---|
| 0 (absent) | No signal of discoloration under the sample area |
| 1 (light) | Discoloration zone only under the sample area |
| 2 (mild) | Discoloration up to 0.5 cm beyond the sample area |
| 3 (moderated) | Discoloration between 0.5 and 1.0 cm beyond the sample area |
| 4 (severe) | Discoloration greater than 1.0 cm beyond the sample area |
Thickness, liquid uptake ability at equilibrium (120 min), water vapor permeability (WVP), and mechanical properties of PVP films. Tests were performed in triplicate (mean ± SD).
| Samples | Thickness (μm) | Liquid Uptake | ||||
|---|---|---|---|---|---|---|
| C-PVP-1:9 | 157 ± 5.39 a | 1579.59 ± 31.16 a | 2.07 | 30.36 ± 2.05 a | 13.41 ± 2.45 a | 3.22 ± 0.647 a |
| C-PVP-1:3 | 163 ± 8.35 a | 760.78 ± 52.64 b | 2.10 | 22.99 ± 5.37 a,c | 12.70 ± 3.78 a | 1.69 ± 0.790 b |
| PVP-SD-1:9 | 123 ± 5.18 b | 983.94 ± 49.90 c | 1.38 | 32.20 ± 3.88 b | 15.43 ± 6.93 a | 4.24 ± 1.11 a,c |
| PVP-SD-1:3 | 122 ± 4.74 b | 606.69 ± 27.10 b,c | 1.43 | 39.25 ±2.67 a,b | 14.72 ± 3.18 a | 5.28 ± 1.77 a,b,c |
Equal letters indicate no statistically significant difference between the samples (Test-t, p > 0.05). WVP = water vapor transmission, Ps = puncture strength, Eb = elongation at the break, Pe = perforation energy.
Figure 1SEM images of the film’s surface (A,C,E,G) and cross-sections (B,D,F,H). A,B: C-PVP-1:9; C,D: C-PVP-1:3; E,F: PVP-SD-1:9; G,H: PVP-SD-1:3.
Figure 2Physicochemical properties of raw materials, physical mixtures (PM), and membranes: (A) FTIR spectra; (B) DRX diffractograms.
Thermal data from the TG-DSC curves.
| Sample | Step 1 | Step 2 | Step 3 | Step 4 | Step 5 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TRange (°C) | Tpeak (°C) | ∆m | TRange (°C) | Tpeak (°C) | ∆m | TRange (°C) | Tpeak (°C) | ∆m | TRange (°C) | Tpeak (°C) | ∆m | TRange (°C) | Tpeak (°C) | |
| C-PVP-1:9 | 30–105 | ↓75 | 6.66 | 105–335 | ↓206 | 26.44 | 360–450 | ↓415 | 39.95 | 450–520 | ↑495 | 16.66 | 520–745 | ↑720 |
| C-PVP-1:3 | 30–120 | ↓82 | 8.97 | 120–370 | ↑274 | 25.32 | 370–445 | ↓415 | 37.30 | 445–530 | ↑505 | 14.96 | 530–750 | ↑730 |
| PVP-SD-1:9 | 30–140 | ↓75 | 10.35 | 140–370 | ↑280 | 25.94 | 370–460 | ↓415 | 33.33 | 460–535 | ↑505 | 12.01 | 535–700 | ↑730 |
| PVP-SD-1:3 | 30–120 | ↓100 | 4.17 | 120–380 | ↑290 | 28.25 | 380–460 | ↑345 | 33.74 | 460–640 | ↑535 | 31.87 | ---- | ---- |
| Chitosan | 30–126 | ↓73 | 8.47 | 149–310 | ↑300 | 36.40 | 310–607 | ↑325 | 53.62 | ---- | ---- | ---- | ---- | ---- |
| PVP | 30–135 | ↓75 | 12.45 | 240–400 | ↓400 | 11.98 | 400–455 | ↓440 | 49.22 | 455–650 | ↑480 | 26.23 | ---- | ---- |
| 242–350 | ↓266 | 31.11 | 350–650 | ↑565 | 68.84 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | |
| Chitosan: PVP | 30–129 | ↓70 | 8.43 | 215–393 | ↑380 | 32.35 | 393–450 | ↓398 | 28.75 | 450–625 | ↑485 | 29.88 | ---- | ---- |
| 30–120 | ↓80 | 3.90 | 240–380 | ↓265 | 19.03 | 380–450 | ↓430 | 30.44 | 450–650 | ↑560 | 45.23 | ---- | ---- | |
| 30–120 | ↓65 | 4.20 | 195–330 | ↑255 ↑265 | 24.94 | 330–600 | ↑525 | 70.46 | ---- | ---- | ---- | ---- | ---- | |
↓ Endo; ↑ Exothermic.
Figure 3TG (A,B) and DSC (C) thermograms of the raw materials, physical mixtures (PM), and membranes.
Bioadhesion strength of the films in porcine skins. The same letters indicate no statistical difference between the samples (T-test, p > 0.05).
| Formulations | Mean ± SD (N) |
|---|---|
| C-PVP-1:9 | 0.1373 ± 0.2240 a |
| C-PVP-1:3 | 0.0629 ± 0.0155 b |
| PVP-SD-1:9 | 0.1142 ± 0.0171 a,c |
| PVP-SD-1:3 | 0.0999 ± 0.0115 d |
Figure 4In vitro release (A) and in vitro cutaneous permeation (B) profiles of trans-resveratrol from the membranes. The profiles are presented as mean ± SD; n = 6.
Trans-resveratrol retention in skin layers after 24 h.
| PVP-SD-1:9 | PVP-SD-1:3 | ||
|---|---|---|---|
|
| Accumulative concentration (μg/cm2) | 47.14 ± 53.41 | 189.56 ± 65.10 |
| Retained drug (%) | 35.10 ± 4.87 | 27.29 ± 4.48 | |
| Dermis and epidermis layers (below the | Accumulative concentration (μg/cm2) | 59.06 ± 25.82 | 117.26 ± 14.53 |
| Retained drug (%) | 18.18 ± 10.28 | 15.59 ± 1.42 | |
Qualitative results of cytotoxicity study.
| Films | Halo (cm) | Cytotoxicity Degree |
|---|---|---|
| Control (+) | 0.9 | Severe |
| Control (−) | 0 | Absent |
| 0.5 | Moderate | |
| C-PVP-1:9 | 0 | Absent |
| C-PVP-1:3 | 0 | Absent |
| PVP-SD-1:9 | 0.4 | Light |
| PVP-SD-1:3 | 0.1 | Light |
Inflammation and inflammation reduction results. Equal letters indicate no statistically significant difference between the samples (Tuckey test, p > 0.05).
| Groups | Mean Inflammation (%) | Reduction in Inflammation (%) |
|---|---|---|
| 30.85 ± 4.29 | 69.15 a | |
| PVP-SD-1:9 | 56.89 ± 7.19 | 43.11 a |
| PVP-SD-1:3 | 33.98 ± 7.09 | 66.02 a |
| C-PVP-1:9 | 80.37 ± 8.04 | 19.63 b,e |
| C-PVP-1:3 | 83.58 ± 21.54 | 15.42 c,e |
| Control + (dexamethasone 1 mg/g) | 24.82 ± 6.96 | 75.18 d |
| Control - (no treatment) | 98.45 ± 7.21 | 1.55 e |
Mean of the values (mm) of the inhibition zone of the samples (One-way ANOVA with Tukey’s post-test, p < 0.001).
| Experimental Group | Mean ± SD |
|---|---|
| C-PVP-1:3 | NI |
| C-PVP-1:9 | NI |
| PVP-SD-1:3 | 4.11 ± 1.53 |
| PVP-SD-1:9 | NI |
| ETH-1:3 | NI |
| ETH-1:9 | NI |
| ETH | NI |
| NC | NI |
NI: not inhibited; ETH: ethanol; NC: negative control.